Use of ipilimumab in the treatment of melanoma
Utkarsh H Acharya, Joanne M Jeter Department of Medicine, Division of Hematology-Oncology, University of Arizona Cancer Center, Tucson, AZ, USA Abstract: Ipilimumab is a monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 that has been approved by the US Food and Drug Administratio...
Guardado en:
Autores principales: | Acharya UH, Jeter JM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a70e26a273564598bfe74b138ede085e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Arginine deprivation therapy for malignant melanoma
por: Yoon JK, et al.
Publicado: (2012) -
Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Matthew D. Tucker, et al.
Publicado: (2021) -
Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
por: Li SY, et al.
Publicado: (2013) -
Management of antipsychotic treatment discontinuation and interruptions using model-based simulations
por: Samtani MN, et al.
Publicado: (2012) -
Chronic hepatitis C: future treatment
por: Wendt A, et al.
Publicado: (2014)